12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tysabri natalizumab: Post-marketing study data

As of Sept. 2, Biogen Idec said that there have been 68 confirmed cases of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri monotherapy for MS since the drug was relaunched in the U.S. and its first international approval in 2006. As of June 30, Biogen Idec reported...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >